Tumor lysis syndrome cost-effectiveness of therapy: Difference between revisions
Created page with "__NOTOC__ {{Tumor lysis syndrome}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{r..." |
Nazia Fuad (talk | contribs) |
||
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tumor lysis syndrome}} | {{Tumor lysis syndrome}} | ||
{{CMG}} {{AE}} {{MJK}} | |||
==Overview== | |||
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of [[rasburicase]] for tumor lysis syndrome prevention may be superior to the daily [[intravenous]] [[allopurinol]]. | |||
==Cost-Effectiveness of Therapy== | |||
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of [[rasburicase]] for tumor lysis syndrome prevention may be superior to the daily [[intravenous]] [[allopurinol]].<ref name="pmid22644973">{{cite journal| author=Patel S, Le A, Gascon S| title=Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome. | journal=Am J Health Syst Pharm | year= 2012 | volume= 69 | issue= 12 | pages= 1015-6 | pmid=22644973 | doi=10.2146/ajhp110656 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22644973 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Medicine]] | ||
Latest revision as of 13:59, 28 August 2018
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome cost-effectiveness of therapy |
|
Tumor lysis syndrome cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Tumor lysis syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.
Cost-Effectiveness of Therapy
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.[1]
References
- ↑ Patel S, Le A, Gascon S (2012). "Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome". Am J Health Syst Pharm. 69 (12): 1015–6. doi:10.2146/ajhp110656. PMID 22644973.